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Suman Mutation and overexpression of p53 occurs in 20-40% of breast cancers and has been shown to
be an independent prognostic indicator. Recently we have demonstrated prostate-specific antigen (PSA)
expression in breast tumours to be suggestive of favourable prognosis, but quantitative relationships between
PSA and p53. and between these and other prognostic factors in breast cancer, have not been investigated.
Time-resolved immunofluorometric procedures were used to quantify both p53 protein and PSA in 200 breast
tumour extracts, which were also assayed for oestrogen (ER) and progesterone receptors (PGR), epidermal
growvth factor receptors (EGFR). cathepsin D and HER-2 neu, and characterised for S-phase fraction and
DNA ploidy. Weak Spearman correlations were found between p53 and ER (r = - 0.18, P = 0.010), PGR
(r = - 0.15. P = 0.0385) and S-phase fraction (r = 0.17. P = 0.016). while PSA was correlated only with PGR
(r = 0.16. P = 0.025). Wilcoxon rank sum analysis revealed that levels of ER (P = 0.0001), PGR (P = 0.0001).
S-phase fraction (P = 0.0001) and EGFR (P= 0.0014) differed significantly between the two groups
categorised as p53 negative or p53 positive. Tumours classifed as PSA negative or PSA positive were found to
differ with respect to PGR (P =0.0091) and S-phase fraction (P = 0.011) in a similar analysis. Contingency
tables indicated significant negative associations betweeh the status of p53 and that of ER (P = 0.003) and
PGR (P =0.001) and between PSA and S-phase fraction (P = 0.012). and positive associations between p53
and EGFR (P = 0.017), HER-2 neu (P = 0.008). S-phase fraction (P = 0.001) and aneuploidy (P= 0.007), and
between PSA and both ER (P = 0.061) and PGR (P = 0.010). No significant associations were found between
p53 and PSA. Our results demonstrate that the presence of p53 in breast tumours relates to several other
variables which are suspected to predict aggressive tumour phenotypes and that the presence of PSA relates to
variables associated with good prognosis.
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Numerous biochemical and cytological features of breast
cancer have been proposed to have prognostic values
(Elledge et al.. 1992: Schwartz et al., 1993). Among these,
genetic alteration of the p53 tumour-suppressor gene has
been reported in hereditary breast cancer syndromes (Fre-
bourg et al.. 1992; Sidransky et al., 1992; Glebov et al.,
1994). in 20-50% of sporadic breast carcinomas (Andersen
et al., 1993; Marchetti et al., 1993; Deng et al., 1994; Faille et
al.. 1994) and at various rates in virtually every other human
malignancy (Levine et al., 1991; Hollstein et al., 1991). The
genetic lesions most often revealed are missense point muta-
tions in evolutionarily conserved regions of the p53 gene
(Mazars et al., 1992), usually accompanied by loss of the
corresponding wild-type allele (Radford et al., 1993; Singh et
al., 1993). Because the expression of mutant, stabilised p53
protein is highly correlated with p53 gene mutation (Davidoff
et al., 1991; Hurlimann et al., 1994; Tsuda and Hirohashi,
1994), demonstration of intracellular p53 protein accumula-
tion, usually by immunohistochemical means, is an estab-
lished alternative to the more laborious molecular techniques.
Both p53 gene mutation and p53 protein overexpression in
tumour tissue have been associated with other cinico-
pathological variables in breast cancer (Barbareschi et al.,
1992; Poller et al., 1992; Elledge et al., 1993; Lipponen et al.,
1993) and with both disease-free and overall survival (Thor et
al., 1992; Allred et al., 1993; Friednrchs et al., 1993; Silves-
trni et al., 1993). although some investigations have not
shown p53 to be an independent predictor of patient out-
come (Ostrowski et alt, 1991: Hanzal et alt, 1992; Isola et al.,
1992). Furthermore, the interrelationships between p53 pro-
tern expression and other prognostic factors have not been
unequivocally and or quantitatively determined, since the
majority of p53 investigations have been carried out with
qualitative or semiquantitative procedures (Diamandis and
Levesque, 1995).
There is no shortage of potential breast cancer prognostic
factors in addition to p53. Undoubtedly, the most important
prognostic factor is disease stage, particularly the extent of
axillary lymph node metastases (Carter et al., 1989). His-
tological grade (Contesso et al., 1989) and type (O'Malley et
al., 1994) of the microscopically examined tumour may also
be considered in treatment decisions. Flow cytometric find-
ings such as the percentage of cells in S-phase (Witzig et al.,
1994) and DNA ploidy (Gnant et al., 1993), as well as the
related expression of the proliferation-associated markers Ki-
67 (Railo et al., 1993) and PCNA (Tahan et al., 1993), have
also been reported to predict tumour behaviour. Especially
evident, however, is the large number of biochemical markers
whose presence, in the case of cathepsin D (CATD) (Isola et
al., 1993), epidermal growth factor receptor (EGFR) (Gas-
parini et al., 1994; Toi et al., 1994), HER-2/neu (Giai et al.,
1994), bcl-2 (Nathan et al., 1994) and p53, or absence, in the
case of pS2 (Thompson et al., 1993) or of oestrogen (ER)
and progesterone (PGR) receptors (Chevallier et al., 1988;
Fisher et al., 1988), may be hallmarks of aggressive tumour
phenotypes. Added to this list might now be prostate-specific
antigen (PSA), which has been recently shown by our group
to be present in extraprostatic tissues (Yu et al., 1994a;
Levesque et al., 1995a; Yu and Diamandis, 1995) and to be
suggestive of favourable prognosis when present in breast
tumour tissue (Yu et al., 1994b, 1995).
In an attempt to contribute to the understanding of the
relationships between p53 and other laboratory measure-
ments on breast tumours, we have used a quantitative
immunofluorometric assay for p53 in breast tumour cytosols
rather than the more common immunohistochemical meth-
ods. A similar procedure was used to quantify PSA, whose
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relationship to p53 expression in breast tumours has not yet
been reported. All tumours were also charactenrsed for 5-
phase fraction, ploidy, steroid hormone receptors, cathepsin
D, EGFR and HER-2/neu. This study was designed to
examine the interrelationships between p53 and PSA with the
aforementioned, relatively well-established prognostic indica-
tors in breast cancer.
Materials and methods
Patient population
For this study, we have used 200 primary breast tumour
tissues deposited at the University of Texas Health Science
Center Tumour Tissue Bank. Follow-up information on these
patients was not available, since they represent newly diag-
nosed cases. All tumours were stored at - 80'C until extrac-
tion was performed (see below). Tumour cellularity exceeded
50% in more than 72% of the tissue specimens, fell to
between 20% and 50% in 26% of the specimens, and was
measured to be between 10% and 20% in fewer than 2% of
the specimens.
p53 and PSA immunofluorometric assay-s
Approximately 200 mg of each tumour specimen was
pulverised while frozen, and the cells were lysed for 30 min
on ice in 1 ml volumes of 50 mM Tris pH 8.0 containing
150 mM sodium chloride, 5 mM EDTA,l 1% Nonidet NP-40.
100 ILg ml- phenylmethylsulphonyl fluoride and Lgml-'
each of aprotinin and leupeptin as proteinase inhibitors. The
extracts were centrifuged at 15 000 g for 30 min at 4'C, and
the supernatants were collected and assayed for total protein
using a bicinchoninic acid-based commercial kit (Pierce,
Rockford. IL, USA) and for p53 and PSA proteins by
immunofluorometric procedures described elsewhere (Has-
sapoglidou et al., 1993; Yu and Diamandis, 1993; Levesque
et al.. 1994). Both immunoassays employed enzymatically
amplified time-resolved fluorometric detection systems (Chris-
topoulos and Diamandis, 1992). We expressed analyte con-
centration relative to the amount of total protein in the tissue
extract.
Tumour extracts were considered PSA positive at concent-
rations equal to or exceeding 0.03 ng mg-', as discussed
elsewhere (Diamandis et al., 1994). Inspection of the fre-
quency distribution of p53 values of all 200 extracts revealed
two populations which could be arbitrarily demarcated into
p53-negative (n = 157. 78%) and p53-positive (n = 43, 22%)
groups by a cut-off level of 5 units per gram of total protein.
This concentration was greater than the 95th percentile of
p53 values determined from 66 breast tissue specimens
resected from healthy women who had cosmetic breast reduc-
tion surgery (data not shown). The p53 standard used was
arbitrary and was established in our laboratory.
Oestrogen andprogesterone receptor assays
Tumour specimens were pulverised in liquid nitrogen,
homogenised in buffer, and the cytosol fractions were
obtained by ultracentrifugation and quantified for steroid
hormone receptors as described by Dressler et al. (1988). The
results of the dual ligand-binding assay, in which dextran-
coated charcoal was used to separate bound from free, were
interpreted by Scatchard analysis (Scatchard, 1949). Protein
concentrations of cytosols were determined by the Lowry
method (Lowry et al., 1951). Cut-off levels for positivity were
greater than or equal to 3 fmol mg-' and greater than or
equal to 5 fmol mg-' for oestrogen and progesterone recep-
tors respectively.
Epidermal grow thfactor receptor assay
Following pulverisation, homogenisation and ultracentrifuga-
tion of tumour tissue performed as above for the steroid
receptor assays. cytosol fractions and suspended fat were
removed. The remaining pellet was resuspended.
homogenised again and briefly centrifuged. Samples prepared
in this way were incubated with fixed concentrations of
radiolabelled EGF and varying concentrations of unlabelled
EGF. Receptor-ligand complexes were separated from free
EGF by polyethyleneglycol before quantification of the
bound fraction by gamma-counting. Non-specific binding
was subtracted before Scatchard analysis of the results, which
were reported as fmol of EGFR per mg of total membrane
protein. Total protein was determined by the Lowry method
(Lowry et al.. 1951). Concentrations of EGFR greater than
10 fmol mg'l were considered positive values.
Cathepsin D assay
Specimen tissue cytosols were prepared by the homogenisa-
tion procedure for routine steroid hormone receptor analyses.
Cathepsin D concentrations of the extracts were measured by
the CD Tissue Extract EIA kit (Triton Diagnostics.
Alameda. CA. USA). which involved the capture of cytosolic
cathepsim D by both a biotinylated monoclonal anti-
cathepsin D antibody and a polyclonal antibody. While the
former antibody allowed binding of cathepsin D-containing
immunocomplexes to streptavidin-coated tubes. the second
permitted detection by serving as the target of anti-rabbit
antibodies conjugated to horseradish peroxidase. which
generated a coloured product. Levels of cathepsin D were
expressed as pmol mg-' protein. The cut-off value for a
positive result was greater than 51 pmol mg-'.
HER-21neu protein expression
Detergent extracts of the frozen, pulvenrsed tumour tissue
were fractionated by polyacrylamide gel electrophoresis and
blotted onto nitrocellulose membranes for Western blotting.
Probing with antiserum specific to HER-2/neu was followed
by staining with a 'MI-labelled secondary antibody to
visualise the stained bands by autoradiography. Den-
sitometry scanning determined the relative level of HER-2
neu protein expression. High and low levels of expression
were determined relative to the HER-2/neu protein level in a
control extract from a breast cancer cell line. Determination
of low or high expression status was as followed by others
(Tandon et al., 1988).
Flow cvtometrv
Specimens were prepared and DNA flow cytometry per-
formed as described elsewhere (Dressler et al.. 1988). Briefly,
tumour tissue was gently homogenised, filtered, centnrfuged
through a double cushion of sucrose, and the cells were
resuspended and counted before being simultaneously lysed
and stained with propidium iodide. Nuclei were collected and
50 000 were analysed on an Epics V flow cytometer (Coulter
Electronics, Hialeah, FL, USA). DNA content and S-phase
fraction were determined from the DNA histograms, in
which diploid populations were defined as having a DNA
index of 1.0, and the percentage of cells in S-phase con-
sidered a favourable prognostic indicator was less than 6.7%.
Statistical analyses
Non-parametnrc statistical analyses. necessitated because of
the non-Gaussian distnrbutions of the values of the prognos-
tic vanables measured. were performed using SAS version 6
software (SAS Institute, Cary. NC. USA). These analyses
included the calculation of Spearman correlation coefficients.
as well as Wilcoxon rank sum tests. with continuity correc-
tion. of the prognostic vanrables when the specimens were
dichotomised by p53 positivity status and of p53 when the
samples were dichotomously categorised based on the status
of the other prognostic variables. Relationships between p53
status and that of each other prognostic factor were also
examined in 2 x 2 contingency tables by the chi-square test
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or by Fisher's exact test, where appropriate. Spearman cor-
relation analyses, Wilcoxon tests and contingency table
analyses were also performed in the same manner to deter-
mine the relationships between PSA and each of the other
factors.
Results
The descriptive statistics of Table I indicate that the distribu-
tions of the values of the biochemical prognostic factors and
of the S-phase fraction were positively skewed. Logarithmic
transformation of the p53 concentrations allowed two
populations to be discerned from the histogram (Figure 1).
Separation of these by an arbitrarily selected p53 cut-off
point was made with considerations of maximising statistical
power and of the detection limit of the p53 immunoassay,
approximately 0.5 U g'. The choice of 5 U g-' divided spec-
imens into 157 p53-negatives (78%) and 43 p53-positives
(22%), rates which are within the range reported by others
for breast cancer (Thor et al., 1992; Allred et al., 1993;
Silvestrini et al., 1993) but lower than the percentage we
found in ovarian cancer using the same immunological pro-
cedure (Levesque et al., 1995b). Prostate-specific antigen is a
newly demonstrated prognostic factor in breast cancer (Yu et
al., 1995) and was found to be present in 26% (n = 52) of the
breast cancer tumour specimens assayed in this study when a
cut-off for positivity of 0.03 ng mg- was used. The distribu-
tion of logarithmically transformed PSA values is shown in
Figure 2. The numbers of specimens positive for each of the
other prognostic variables were 172 (86%) for oestrogen
receptors, 120 (60%) for progesterone receptors, 71 (36%)
for cathepsin D and 41 (21%) for HER-2/neu expression. In
addition, 54% (n = 108) of the specimens were found to have
an aneuploid DNA content, while 36% (n = 72) displayed an
S-phase fraction greater than 6.7%.
Statistically significant, but weak, negative correlations
between p53 levels and both steroid hormone receptor con-
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centrations were found, as was the weak positive correlation
between p53 and S-phase fraction (Table II). However,
values of p53 were not statistically significantly correlated
with those of cathepsin D, epidermal growth factor receptors
or PSA. While PSA levels were not correlated with those of
oestrogen receptors, cathepsin D, epidermal growth factor
receptors or with the S-phase fraction, a significant positive
correlation, albeit weak, was revealed between PSA and pro-
gesterone receptor concentrations.
Specimens divided into two groups on the basis of p53-
positivity status using the 5 U g- cut-off were shown to
differ with respect to the values of hormone receptor levels
(P = 0.0001), S-phase fraction (P = 0.0001) and EGF recep-
tor levels (P = 0.0203), as determined by the Wilcoxon rank
sum analyses of Table III. This is illustrated by the much
lower median oestrogen and progesterone receptor concentra-
tions of specimens with p53 levels greater than or equal to
5U g-' compared with p53-negative specimens (P =0.0001
for each), reflecting the negative Spearman correlations
between p53 and the steroid hormone receptors. Similarly,
the higher median S-phase fraction of 9.4% in the p53-
positive group (P= 0.0001) is consistent with the positive
Spearman correlation between these variables. Unlike the
results of the correlation analysis, the Wilcoxon analysis of
Table III indicated a statistically significant difference in
EGFR values between p53-negative and p53-positive groups
(P = 0.0203), although it is difficult to appreciate from the
table. Cathepsin D and PSA did not, however, differ
significantly between p53-negative and p53-positive groups.
Differences between PSA-negative and PSA-positive
tumours with respect to the values of the other markers were
also demonstrated by the Wilcoxon analyses of Table IV. As
expected from the correlation analysis, it was found that
tissue specimens with PSA concentrations equal to or exceed-
ing 0.03 ng mg-' had progesterone receptor values above
those of PSA-negative tumours, shown by the almost 3-fold
higher median progesterone receptor level in the PSA-
positive group (P = 0.0091). Proliferative activity, represented
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Figure 1 Frequency distribution of p53 protein levels in 200
breast tumour extracts, showing cut-off for positivity selected.
l= 52)
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Fgure 2 Frequency distribution of PSA levels in 200 breast
tumour extracts, showing cut-off for positivity selected.
Table I Descriptive statistics of quantitatively analysed prognostic indicators in 200
breast tumnours
Prognostic variablea Mean s.d. Median Minimum Maxinum
ER 140 163 81 0 737
PGR 201 405 70 0 2457
SPHASE 6.6 5.7 4.3 0.1 29
CATD 47.9 27.2 41.3 7.2 162
EGFR 19.4 141 0 0 1970
PSA 0.18 0.89 0.018 0.002 10
p53 18.8 48.9 1.8 0 336
aValues of prognostic indicators are expressed as follows: oestrogen and
progesterone receptors in finolmg-; S-phase fraction as the percentage of cells in
S-phase; cathepsin D in pmolmg-'; epidermal growth factor receptors in fmol mg-';
prostate specific antigen in ngmg-'; and p53 in Ug-'.Table n Spearman correlation analysis of p53 and
factorsa
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PSA versus other prognostic
ER PGR S-phase CATD EGFR PSA
p53 *s other factors
r, -0.18 -0.15 0.17 0.056 0.045 -0.035
P-value 0.010 0.038 0.016 0.43 0.53 0.62
PSA vs other factors
r5 0.0084 0.16 - 0.027 0.034 0.0058
P-value 0.91 0.025 0.70 0.64 0.93
ar, Spearman correlation coefficient.
Table m Wilcoxon rank sum analysis of other prognostic factors when p53 level is
represented as a dichotomous variable
p53<5 Ur' (n = 157) p53 ) 5Ug-U (n = 43}
Factor' MWedian (Range) Median (Range) P-value
ER 100 (0-737) 13.0 (0-297) 0.0001
PGR 97 (0-2457) 0.0 (0- 1811) 0.0001
S-phase 3.7 (0.1-29) 9.4 (1.8-25) 0.0001
CATD 43 (7.2-147) 40 (13.6-162) 0.76
EGFR 0.0 (0-1970) 0.0 (0-76) 0.020
PSA 0.017 (0.003-5.5) 0.019 (0.002-10.0) 0.91
aFor units of all prognostic factors see Table I.
Table IV Wilcoxon rank sum analysis of other prognostic factors when PSA level is
represented as a dichotomous variable
PSA <0.03 ng mg PSA ) 0.03 ng mg'
(n=148} (n=52)
Factora Median (RangeJ Median (Range) P-value
ER 77 (0-737) 93 (0-554) 0.29
PGR 40 (0-2457) 114 (0-2123) 0.0091
S-phase 5.2 (0.1 -29.1) 3.5 (0.2-18.7) 0.011
CATD 43 (8.8-162) 40 (7.2-147) 0.58
EGFR 0.0 (0- 1970) 0.0 (0-241) 0.27
p53 1.9 (0-336) 1.8 (0-213) 0.29
aFor units of all prognostic factors see Table I.
as the fraction of cells in S-phase, was significantly lower in
PSA-positive tumours than in tumours with negative PSA
status (P = 0.011). No other significant differences were evi-
dent in these analyses. Because the assay of HER-2/neu
expression yielded only the dichotomous absence or presence
of HER-2/neu protein, it was excluded from the Wilcoxon
analysis of Table IV.
The results of the reciprocal Wilcoxon analyses, that is of
differences in p53 levels when p53 was represented as a
continuous variable, between groups defined as aneuploid or
diploid gave the following results: the median p53 value for
diploid tumours was 1.5 U g-', compared with the median
p53 for aneuploid tumours, which was 2.0 U g-' (P = 0.038).
Corresponding median PSA values between diploid and
aneuploid tumours were 0.019ngmg-' and 0.016ngmg-1
respectively (P=0.19). While p53 levels were also found to
differ significantly between PGR-negative and PGR-positive
groups (P = 0.009), and there was a trend for PSA to do so,
but in the opposite direction (P = 0.06), neither p53 nor PSA
differed across tumours divided on the basis of any other
factor (data not shown).
Relationships between the status of p53 in the tumour
specimens and the status of each additional biochemical or
cytological variable were also evaluated by contingency table
analysis (Table V). Both ER-positive (P =0.003) and PGR-
positive (P<0.001) specimens tended overwhelmingly to
have p53 concentrations less than 5 U g-', agreeing with the
results of the Wilcoxon rank sum analysis of Table III. The
presence of mutant p53 was also seen more frequently in
DNA aneuploid tumours, while diploidy was associated with
Table V Contingency table analysis of associations between p53
and other prognostic factors
Nwnber of patients (%}
Factor p53<5Ug g p53>5Ug-' P-value
ER
ER- 16 (57.1) 12 (42.9)
ER+ 141 (82.0) 31 (18.0) 0.003
PGR
PGR- 51 (63.8) 29 (36.2) <
PGR+ 106 (88.3) 14 (11.7) 0.001
CATD
CATD- 102 (79.1) 27 (21.0) 0.79 CATD+ 55 (77.5) 16 (22.5)
EGFR
EGFR- 126 (82.3) 27 (17.7) 0017
EGFR+ 31 (66.0) 16 (34.0)
PSA
PSA- 112 (75.7) 36 (24.3) 0.10 PSA+ 45 (86.5) 7 (13.5)
HER2
HER2- 131 (82.4) 28 (17.6) 0.008 HER2+ 26 (63.4) 15 (36.6)
Ploidy
Diploid 80 (87.0) 12 (13.0) 0007
Aneuploid 77 (71.3) 31 (28.7)
S-phase
<6.7% 113 (87.6) 16 (12.4) <0001
) 6.7% 44 (62.0) 27 (38.0)p53pn aerW prntisspecif mnlnkes caicer
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Table VI Contingency table analysis of associations between PSA and other
prognostic factors
Number of patients (%)
Factor PSA <0.03 ngmg-' PSA > 0.03 ngmg-' P-value
ER
ER- 25 (89.3) 3 (10.7)
ER- 123 (71.5) 49 (28.5) 0.061
PGR
PGR- 67 (83.8) 13 (16.2) 0010
PGR' 81 (67.5) 39 (32.5)
CATD
CATD- 92 (71.3) 37 (28.7) 0.24 CATD 56 (77.5) 15 (21.1)
EGFR
EGFR- 110 (71.9) 43 (28.1) 022
EGFR+ 38 (80.9) 9 (19.1)
HER2
HER2- 119 (74.8) 40 (25.2) 0.59 HER2- 29 (70.7) 12 (29.3)
Ploidy
Diploid 63 (68.5) 29 (31.5) 010
Aneuploid 85 (78.7) 23 (21.3)
S-phase
<6.7% 88 (68.2) 41 (31.8) 0.01 6.70 60 (845) 11 (15.5) 0
p53-negative status (P = 0.007). A positive association was
also found between p53 and EGFR (P = 0.017). shown by
differences between the p53-positive proportions of EGFR-
positive specimens (34%) vs EGFR-negative specimens
(17.7%). When the absence or presence of the categorical
variable HER-2, neu protein expression was related to
positivity status for p53 protein, a positive association
(P=0.008) was found which had escaped detection by the
Wilcoxon procedure using continuously distributed p53
values. Associations were not found between p53 and cathep-
sin D or PSA at the 5 U g'- cut-off point or at any other
cut-off point tested in contingency tables (data not shown).
The tendency of breast tumour specimens to be co-
classified as positive for both PSA and PGR (P = 0.010)
again indicated the strong association between these variables
(Table VI). Also significant was the association between S-
phase fraction and PSA, such that PSA-positive specimens
were less likely to have S-phase percentages considered signs
of poor prognosis (P = 0.012). The finding of a trend relating
ER status to that of PSA in the contingency table analysis
(P = 0.061) but not in the Wilcoxon rank sum or correlation
procedures exemplified the weaker association between PSA
status and this steroid hormone receptor. Whether or not
specimens were PSA positive provided no significant inform-
ation as to their status ofcathepsin D, EGFR or HER-2/neu
expression, or of their genome copy number, although there
was a trend for PSA-positive tumour to be diploid
(P = 0.10).
The p53 tumour-suppressor protein is a nuclear transcription
factor shown to regulate the expression of genes mediating
cell cycle arrest (Kuerbitz et al., 1992) and apoptosis (Lowe
et al., 1993) in response to DNA strand cleavage. Mutations
in the gene leading to non-functional or even dominant
oncogenic forms of the protein would be expected to confer a
proliferative advantage, an escape from normal programmed
cell death and possibly even a therapy-resistant phenotype
when p53 function becomes rate limiting for cell growth or
survival. Given the abundant in vitro evidence implicating a
role for abrogation of p53 function in breast cancer develop-
ment (Vojtesek and Lane. 1993; Negrini et al.. 1994). it is not
surprising that p53 mutation, and hence p53 protein
accumulation in tumour cells, would correlate with other
markers of highly proliferative, aggressive cancers. In fact,
other workers have found p53 alterations to be associated
with late stage (Thor et al., 1992; Andersen et al.. 1993;
Stenmark-Askmalm et al., 1994), high grade (Thor et al.,
1992; Silvestrini et al., 1993), comedo, medullary or ductal
histological types (Marchetti et al., 1993; O'Malley et al.,
1994), negative steroid receptor status (Horak et al., 1991;
Isola et al., 1992; Poller et al., 1992), expression of cathepsin
D (Domagala et al., 1993), EGFR (Barbareschi et al., 1992;
Gasparini et al., 1994) or HER-2/neu (Isola et al., 1992;
Poller et al., 1992; Andersen et al., 1993), elevated S-phase
fraction (Lipponen et al., 1993; Meyer and He, 1994) and
aneuploid DNA content (Isola et al., 1992; Stenmark-
Askmalm et al., 1994). In the vast majority of these studies,
immunohistochemical approaches to detect p53 protein, or
more rarely single-strand conformation polymorphism
(SSCP) analysis coupled with direct sequencing, were used. In
contrast to these studies, we have used an immunological
assay to measure p53 concentration in breast tumour ex-
tracts.
Application of our p53 immunoassay, as previously des-
cribed (Levesque et al., 1994), to the 200 breast tumour
extracts yielded a p53-positivity rate of 22% (43/200). Selec-
tion of the cut-off point at SU g-' was based on the fre-
quency distribution of p53 values (Figure 1) in the study
sample and the results of p53 quantification in normal breast
tissue showing the 95th percentile to be less than 2 U g-'
(data not shown). The receiver operator characteristic (ROC)
procedure would have been inappropriate for cut-off point
selection since a gold standard for breast cancer prognostica-
tion does not exist. Tumour specimens were thus classified
into p53-negative and p53-positive groups in this way.
Criteria for determining the status for each of the other
markers, including PSA, are described above.
Consistent with our previous study of over 950 breast
tumour cytosolic extracts (Levesque et al., 1994), we show
here weak negative correlations between levels of p53 and
both ER and PGR, relationships which were further illus-
trated by the results of the Wilcoxon and contingency table
analyses. We have previously proposed that the greater
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strength of association between p53 and PGR might reflect a
more direct regulatory link and that the association between
p53 and ER might be indirect in nature (Levesque et al..
1994). However, in another report (Sheikh et al.. 1993) a
negative correlation was found between ER status and levels
of mRNA for mdm2. which can bind to, and inactivate p53
protein. While this may account for p53 functional inactiva-
tion. mdm2 complexation with p53 might not decrease the
latter's accumulation or detectability.
Tumours whose cells display p53 accumulation are most
frequently those which are highly proliferative. This is dem-
onstrated by the weak positive correlation between p53 and
S-phase fraction. and by the increased S-phase fraction of
p53-positive tumours in the Wilcoxon analysis of Table III.
Also, we have found that aneuploid tumours tend to have
higher concentrations of p53 than diploid tumours, sup-
ported by the positive association observed in the con-
tingency table analysis between aneuploidy and p53 positivity
(Table V).
Associations between the concentrations of p53 protein
and the expression of other biochemical prognostic markers
were also revealed. EGFR levels were found to be increased
in p53-positive breast cancers, shown most clearly when both
p53 and EGFR are represented as dichotomous variables
(Table V). Also shown from contingency table analysis is a
highly significant association between p53 and HER-2/neu
expression, a relationship not examined in Wilcoxon rank
sum tests since HER-2,neu is not a continuous numerical
variable. No significant relationships were found between p53
status and status of either cathepsin D or PSA. Lack of an
association between p53 and cathepsin D has been reported
by others (Isola et al., 1993), although the two markers have
been found to be inversely related in another report
(Domagala et al., 1993). It is implicit from this latter report,
however, that the association between p53 and cathepsin D
may be obscured by the particular combination of his-
tological types included for study, resulting primarily from
the large differences in p53-positivity rates between ductal
and lobular carcinomas. Because information regarding the
histological types of the breast tumours studied were not
available, we were unable to consider this issue. Finally, our
findings that p53 and PSA were not significantly associated
in any of the statistical analyses performed are concordant
with our previous results (Levesque et al., 1994). In this
study, we have shown that PSA is strongly associated with
low S-phase fraction and is found more frequently in diploid
tumours (Table VI).
Although we have used quantitative assays for both p53
and PSA proteins in breast tumour cytosolic extracts, our
data may be somewhat biased since approximately 28% of
the specimens contained only 20-50% malignant cells and
approximately 2% of the tissues had tumour cellularities
between 10% and 20%. The vast majority (72%) of the
specimens, however, contained mostly tumour cells.
In summary, we provide for the first time quantitative
evidence that p53 accumulation in breast tumour tissue is
associated with markers of increased cellular proliferation
and with the expression of other growth-related proteins, all
of which may indicate unfavourable prognosis. We also dem-
onstrate the utility of an ELISA-type immunological assay
for p53 protein quantification in breast tumour cytosols. As
patient follow-up was not possible in this study, determina-
tion of the prognostic usefulness of immunofluorometrically
measured p53 protein in breast cancer must await further
studies. Furthermore, we have demonstrated that PSA, a new
favourable prognostic indicator in breast cancer, is closely
associated with other favourable prognostic markers. We
expect that our data may have utility in the design and
selection of prognostic panels in breast cancer based on
quantitative measurements in a single tumour extract.
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